INFLARX N.V.
|
||
Date: November 15, 2021
|
By:
|
/s/ Niels Riedemann
|
Name: Niels Riedemann
|
||
Title: Chief Executive Officer
|
Exhibit No.
|
Description
|
|
Press Release, dated November 15, 2021
|
||
99.2 |
InflaRx N.V. November 2021 Corporate Presentation
|
• |
Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients; vilobelimab demonstrated comparable efficacy to standard of care
|
• |
Use of vilobelimab instead of glucorticoids led to substantially lower observed glucocorticoid toxicity
|
• |
Vilobelimab demonstrated a good safety and tolerability profile; vilobelimab only treatment arm had lowest number of reported treatment emergent adverse events
|
Dose Groups
No. of evaluable patients
|
|
vilobelimab (No GC)
N=18
|
SDGC
N=23
|
|
vilobelimab + RDGC
N=13
|
|
Pooled vilobelimab
N=31
|
|||||||
Clinical Remission at Week 16 [N (%)]
|
14 (77.8%)
|
|
20 (87.0%)
|
10 (76.9%)
|
|
24 (77.4%)
|
|
|||||||
No Clinical Remission [N (%)]
|
4 (22.2%)
|
|
3 (13.0%)
|
3 (23.1%)
|
|
7 (22.6%)
|
|
|||||||
Missing at week 16
|
0
|
1 |
2
|
2
|
vilobelimab (No GC)
N=18
|
SDGC
N=24
|
vilobelimab + RDGC
N=15
|
||||||||||||||||||||||||||
Pat N
|
(Pat %)
|
Events
|
Pat N
|
(Pat %)
|
Events
|
Pat N
|
(Pat %)
|
Events
|
||||||||||||||||||||
TEAEs
|
16
|
(88.9%)
|
81
|
24
|
(100.0%)
|
180
|
15
|
(100.0%)
|
89
|
|||||||||||||||||||
Serious TEAEs
|
5
|
(27.8%)
|
5
|
4
|
(16.7%)
|
6
|
3
|
(20.0%)
|
3
|
|||||||||||||||||||
TEAEs rated as related to vilobelimab
|
6
|
(33.3%)
|
8
|
18
|
(75.0%)
|
40
|
6
|
(40.0%)
|
9
|
|||||||||||||||||||
TEAEs rated as related to GC
|
7
|
(38.9%)
|
21
|
18
|
(75.0%)
|
105
|
11
|
(73.3%)
|
24
|
|||||||||||||||||||
Serious TEAEs rated as related to vilobelimab
|
1
|
(5.6%)
|
1
|
1
|
(4.2%)
|
1
|
0
|
(0.0%)
|
0
|
|||||||||||||||||||
Serious TEAEs rated as related to GC
|
2
|
(11.1%)
|
2
|
3
|
(12.5%)
|
4
|
0
|
(0.0%)
|
0
|
>/\>@J"&+2?A[]W[+K_B9?XL"6QL&]NTT@_[X4_WJ
MYKZG;3^%%'1_!-KH]C!JWBEY;.TE7?:Z;"0+N]'8@'_5Q_\ 31NO\(-1Z_XF
MNO$"P6_EQ6&E6W_'KIEH"L$ ]<=6<]W;)-9][>76K7TU[?7$EW=S-NDGF;:RKJ]Z\U7NKX<\UD7=[P>:9#98NK[DXK)N;_[W-5;J]Z\UDW-X>>:9E)EN
MXON3\U06]Z/+FR<\BLFXO.3S3+6Z'ES'K5Q6IS29T>H7):X/. "BG]/K5>.4?C]?_ *U=,MSF.X^%, N?$B_+G%U:?K*/>OT)^)?A
M")_-+&->/XF'I7YX?"V\L[?Q%!]ME,*/>VH1ESU$@)S[8K],_%6M^ +IG,<>RUY^*C\+.JC)ZI?F?(UUXFUKX+>.M+\5^%GCEO[2?$T7F;
M4D@/WT;U4CC'T/:OTP^$_P 4M$^,?@?3_$^A3;[6Y7;+"Q^>WF'WXG'8@_F,
M'O7PC\0M/TJ^606/A76+D9R'>S,8_P#'B*P_V>_C1JG[/GQ&9KS2;BU\&:JZ
MQZG [J3$>BW"J/XE[^JY]!7#8]"$GLS].6%-VU3M-X6[U[3;4KB*.,1
M8QR<$X8>^*C^T16>L)OTNU0^86,I)9E^8Y(_I702:K*VM6J06]JD$PW*QB#2
M >Q/>O<4I6T1PVCU9&UC);1BQOHFN;0G?'L))3/=?ZBNLTVQO&\,^%;$W<%Y
M!9ZKYX@6%A<6T?J['@I^M5([^_:,-%= 8/!V 9]O8T][Z^62UE%W/YJ2Y,+G
M@\>G<>U8R3DK#C*,6=CXHCN=
L*M?%/0](U&[LS#<32P2&-O*LUVY'8$FN#C\8+>?$H^(K:QD^SR1-
M$(9=D;8V 9QT'-=E?:G\-X9I29=)(WG#?:221FN"N?%OA&U^)T=REY8IH*JR
MG!+1 ^6 /_'J]9'("/C^+'0UZ-.ZBFCBJ6;Y3FI_M&F^)-7
M